Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...
| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of ...
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The ...
Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...
Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...
Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer antidepressant, reduced bouts of cataplexy and other narcolepsy symptoms in ...
On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback